A strategy to own twin drugs through Korean domestic branches spreads in the pharmaceutical industry

Korean pharmaceutical companies owning original medicines are getting ready for the patent expirations in various ways, too.

Several companies are implementing a strategy to commercialize twin medicines with the same component as the original one to block generics.

On the 14th, JW Life Science was approved for a dyspepsia medicine ‘Prigaton’ with a generic component, Itopride HCI.

The medici...